Furthermore, co-treatment with LicoA and Sor resulted in significant synergistic anti-metastatic effects on human hepatocellular carcinoma via the inactivation of the MKK4/JNK pathway and the downregulation of uPA [43]. This evidence concerns the gene MAPK8 and hepatocellular carcinoma.